Legochem Bioscience Inc. (LCB) has entered into a research collaboration and license agreement with Amgen Inc., granting Amgen rights to research, develop and commercialize antibody-drug conjugates (ADCs) directed against up to 5 targets selected by Amgen based on LCB’s proprietary Conjuall ADC technology.
Affimed NV has received clearance of a clinical trial application (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM) for a phase I study of AFM-28 (AFM28-101) in CD123-positive relapsed or refractory acute myeloid leukemia (AML).
Elpiscience Biopharmaceuticals Inc. has announced Center of Drug Evaluation (CDE) clearance of its IND application for ES-014 for a phase I study in patients with advanced solid tumors.
The FDA has cleared an IND for a clinical trial in the U.S. of NBL-020, a fully human antibody drug independently developed by CSPC Pharmaceutical Group Ltd.'s subsidiary Novarock Biotherapeutics Ltd., for the treatment of advanced solid tumors.
Triple-negative breast cancer (TNBC) has a diverse etiology, with high unmet clinical needs. Researchers from Tavotek Biotherapeutics (Hong Kong) Ltd. presented data on TAVO-412, a trispecific EGFR/cMET/VEGF (2:1:1 binding arm ratio) antibody for the potential treatment of TNBC.
Although ovarian cancers appear to be immunologically active, they do not respond well to immunotherapy in the clinic. In a study published on Dec. 14, 2022, in Nature, a multidisciplinary team at Memorial Sloan Kettering Cancer Center (MSK) led by Sohrab Shah and Dmitriy Zamarin has uncovered several mechanisms of immune evasion that can help explain why ovarian cancers have been resistant to immunotherapy to date.
RSS
